4.02
+0.12(+3.08%)
Currency In USD
| Previous Close | 3.9 |
| Open | 3.9 |
| Day High | 4.07 |
| Day Low | 3.87 |
| 52-Week High | 5.96 |
| 52-Week Low | 2.65 |
| Volume | 670,708 |
| Average Volume | 476,688 |
| Market Cap | 223.5M |
| PE | -1.85 |
| EPS | -2.17 |
| Moving Average 50 Days | 4.17 |
| Moving Average 200 Days | 3.77 |
| Change | 0.12 |
If you invested $1000 in Voyager Therapeutics, Inc. (VYGR) 10 years ago, it would be worth $287.14 as of January 14, 2026 at a share price of $4.02. Whereas If you bought $1000 worth of Voyager Therapeutics, Inc. (VYGR) shares 5 years ago, it would be worth $450.67 as of January 14, 2026 at a share price of $4.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
GlobeNewswire Inc.
Nov 10, 2025 1:01 PM GMT
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Na
Voyager to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 26, 2025 11:00 AM GMT
LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the followi
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
GlobeNewswire Inc.
Jul 16, 2025 11:00 AM GMT
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’s disease franchise now include